Caffeine; the Forgotten Potential for Parkinson's Disease.
Ahmed Negida1, Mohamed Elfil2, Attia2
1Faculty of Medicine, Zagazig University, Zagazig, El-Sharkia, Postal Code: 44519. Egypt.
CNS & Neurological Disorders Drug Targets
|November 9, 2016
Summary
Caffeine may reduce Parkinson's disease (PD) risk and slow progression by preventing Lewy body aggregation and reducing oxidative stress. It also enhances dopamine release and may improve treatment outcomes as an adjuvant therapy.
Area of Science:
- Neuroscience
- Pharmacology
Background:
- Parkinson's disease (PD) is a neurodegenerative disorder marked by dopaminergic neuron loss and Lewy bodies.
- It is the second most prevalent neurological disorder globally.
Purpose of the Study:
- To review the multifaceted roles of caffeine in Parkinson's disease.
- To explore caffeine's potential as a neuroprotective agent and adjuvant therapy for PD.
Main Methods:
- Literature review of epidemiological, molecular, and clinical studies on caffeine and PD.
- Analysis of caffeine's effects on alpha-synuclein aggregation, oxidative stress, and dopamine pathways.
Main Results:
- Epidemiological studies link caffeine intake to reduced PD risk, particularly in susceptible individuals.
- Caffeine inhibits alpha-synuclein aggregation, reduces oxidative stress, and enhances dopamine release via A2a receptor antagonism.
- Caffeine may improve levodopa pharmacokinetics, reduce dyskinesia, and alleviate gait issues in PD patients.
Conclusions:
- Caffeine demonstrates significant neuroprotective potential in Parkinson's disease.
- It shows promise as an add-on therapy to conventional antiparkinsonian treatments.
Related Concept Videos
01:24Parkinson's Disease: Treatment
1.3K
Neurodegenerative disorders, such as Parkinson's Disease (PD), involve the gradual and irreversible destruction of neurons in particular brain areas. These disorders exhibit standard features like proteinopathies, selective vulnerability of some neurons, and an interaction of intrinsic properties, genetics, and environmental influences in neural injury.
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
1.3K
01:15Parkinson's Disease: Overview
2.3K
Neurodegenerative disorders are progressive diseases that cause irreversible damage and loss to neurons in specific brain areas. Examples of these disorders include Parkinson's disease, Alzheimer's disease, Multiple Sclerosis (MS), and Amyotrophic Lateral Sclerosis (ALS). These disorders share characteristics such as proteinopathies, selective neuronal vulnerability, and a complex interplay between genetic and environmental factors. The primary therapeutic goal for these conditions is...
2.3K
01:37Neural Regulation
44.0K
Digestion begins with a cephalic phase that prepares the digestive system to receive food. When our brain processes visual or olfactory information about food, it triggers impulses in the cranial nerves innervating the salivary glands and stomach to prepare for food.
44.0K
01:15Chronopharmacokinetics: Circadian Rhythms and Influence on Drug Response
436
Circadian rhythms are cyclic changes that are crucial in plasma drug concentrations. Various standard circadian parameters, including core body temperature, heart rate, and other cardiovascular factors, directly impact disease states and the therapeutic response to drug therapy.
The time of drug administration is an important factor to consider, as it can influence the toxic dose of a drug. For example, a study conducted by Prins et al. in 1997 examined the effects of the timing of...
The time of drug administration is an important factor to consider, as it can influence the toxic dose of a drug. For example, a study conducted by Prins et al. in 1997 examined the effects of the timing of...
436
01:27Pharmacodynamics in Geriatric Patients: Effects of Age
307
Age-related pharmacokinetic changes are extensively documented, but understanding age-related pharmacodynamic alterations is relatively limited. This knowledge gap can be partly attributed to the complexity of developing appropriate measures of drug responses compared to bioanalytical methods for determining drug concentrations.Most information regarding age-related differences in human pharmacodynamics originates from cross-sectional studies. However, these studies assume that observed mean...
307
01:23Nonlinear Pharmacokinetics: Dependence of Elimination Half-Life and Dose Clearance
829
The elimination half-life and drug clearance of drugs following nonlinear kinetics can vary with dosage. The Michaelis-Menten parameters and drug concentration influence these factors. As the dose increases, the elimination half-life tends to lengthen, resulting in a reduction in clearance and a disproportionately larger area under the curve. The total clearance can be derived from the Michaelis-Menten equation for drugs following a one-compartment model.
A study on guinea pigs examined the...
A study on guinea pigs examined the...
829